nivolumab + capecitabine + oxaliplatin

**Nivolumab + capecitabine + oxaliplatin** is a combination regimen consisting of a programmed death-1 (PD-1) immune checkpoint inhibitor (nivolumab), an oral fluoropyrimidine (capecitabine), and a platinum-based chemotherapeutic (oxaliplatin). This combination is approved and used for first-line treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, especially in patients with HER2-negative tumors expressing PD-L1 (CPS ≥5)[3][5]. Nivolumab acts by blocking PD-1 receptors, enabling T cells to recognize and kill tumor cells; capecitabine is a prodrug of 5-fluorouracil, inhibiting thymidylate synthase and interrupting DNA synthesis in rapidly dividing cells; oxaliplatin forms platinum-DNA adducts, leading to apoptosis. The combination leverages chemotherapy-induced immunogenic cell death to synergize immune response with checkpoint blockade[1][9].

Brand names

Opdivo (nivolumab)Xeloda (capecitabine)None (oxaliplatin usually under generic name; sometimes Eloxatin)

Other names

CapeOX (capecitabine + oxaliplatin)XELOX (capecitabine + oxaliplatin)nivolumab + XELOXnivolumab + CapeOX